| Patient | Higuchi Ichiyō |
|---|---|
| Date of birth | 1872-05-02 |
| Identifiers | MRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108 |
| Document date | 1896-04-17 |
| Author | Aiko Lindgren-Tanaka, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Results visit: sputum tests, with infectious diseases consultation the same day. [S]
Ms. Higuchi returns three days after her first visit for her results and is seen by Dr. Abernathy-Okoye of infectious diseases today. She brought the second and third sputum specimens, the last collected on waking this morning. Since her first visit she has stayed home, slept in her own room with the window open, and worn a surgical mask in the shared rooms; no one has visited. The cough is unchanged, with a little white sputum and no blood, and she still has evening fevers and night sweats. She is eating a little more since the dietitian's first call. She has not written since her first visit. She is worried about the people she lives with and about the cost of treatment. [S]
| Element | Detail |
|---|---|
| Symptoms | Cough, evening fevers and night sweats unchanged; no hemoptysis |
| Precautions | At home with a mask in shared rooms; no visitors |
| Testing | Three sputum specimens complete; blood results back |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Cough with a little white sputum; no blood; breathless on the stairs |
| Constitutional | Positive | Evening fevers, night sweats and tiredness |
| Eyes | Negative | No blurred vision |
| Psychiatric | Positive | Worried about her household and costs; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 1896-04-17 to 1896-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 1896-04-17 to 1896-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1896-04-17 | Body height | 148 | cm | S |
| 1896-04-17 | Body weight | 38.4 | kg | S |
| 1896-04-17 | Body mass index (BMI) [Ratio] | 17.5 | kg/m2 | S |
| 1896-04-17 | Systolic blood pressure | 96 | mm[Hg] | S |
| 1896-04-17 | Diastolic blood pressure | 60 | mm[Hg] | S |
| 1896-04-17 | Heart rate | 100 | /min | S |
| 1896-04-17 | Respiratory rate | 20 | /min | S |
| 1896-04-17 | Body temperature | 37.6 | Cel | S |
| 1896-04-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
Vital signs recorded on 1896-04-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin and tired; weight 38.4 kg; temperature 37.6 °C, pulse 100; seen in an airborne infection isolation room with staff wearing respirators |
| Respiratory | Fine crackles over the right upper zone; no wheeze |
| Eyes | No icterus |
| Abdomen | Soft and non-tender; liver not enlarged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed | R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | active | confirmed | A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Sputum smear and culture | At diagnosis, at two weeks, and at the end of the intensive phase (two months) | Completed today | Three specimens, one on waking: smears negative for acid-fast bacilli; liquid and solid cultures pending |
| Laboratory | Xpert MTB/RIF Ultra (nucleic acid amplification with rifampin resistance) | At diagnosis | Completed today | Mycobacterium tuberculosis detected, low; rifampin resistance not detected |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Ordered | Phenotypic susceptibility to first-line drugs to be set up on the first positive culture |
| Laboratory | HIV test | At diagnosis | Up to date | HIV-1/2 antigen and antibody test negative |
| Laboratory | Hepatitis B and C serology | At diagnosis | Up to date | Hepatitis B surface antigen, surface antibody and core antibody negative (not immune); hepatitis C antibody negative |
| Laboratory | Pregnancy test | Before starting treatment in a woman who could be pregnant | Up to date | Negative at intake |
| Laboratory | Diabetes screen (hemoglobin A1c) | At diagnosis | Up to date | 5.1% at intake |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Up to date | Normal at intake (ALT 12, AST 19 U/L, bilirubin 0.4 mg/dL); albumin 3.3 g/dL |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Up to date | 85 letters in each eye with normal color vision at intake, before ethambutol |
| Imaging | Chest X-ray | At diagnosis and at the end of treatment as a new baseline | Up to date | Right upper lobe opacities without a cavity at intake |
| Medication safety | Regimen choice and weight-based doses | At the start of treatment | Completed today | Standard six-month regimen; not eligible for the four-month rifapentine-moxifloxacin regimen at 38.5 kg. Isoniazid 5, rifampin 12, pyrazinamide 26 and ethambutol 16 mg/kg |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | First dose observed in the clinic; video-observed therapy from tomorrow |
| Medication safety | Rifampin drug-interaction review, including hormonal contraception | With every new medicine | Completed today | No other medicines; told that rifampin weakens hormonal contraceptives and interacts with many drugs |
| Self-management | Home precautions and the criteria for release | Until two weeks of treatment with clinical improvement, for smear-negative disease | Completed today | Precautions at home continue; smear-negative, so treated as an outpatient |
| Referral | Notification to the public health center (Infectious Diseases Control Law, Article 12) | At once on diagnosis | Completed today | Notified today; the center was told of the suspected case at intake |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Referred | The public health center will assess her household and close contacts; their results belong to their own records |
| Referral | Public funding and other help with costs | At diagnosis | Completed today | Public funding application completed with the social worker |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 38.4 kg; dietitian and supplement drinks |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Up to date | PHQ-9 8 at intake, item 9 scored 0 |
| Referral | Infectious diseases consultation | Once at diagnosis, then as advised | Completed today | Seen today by Dr. Abernathy-Okoye |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); 結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law) (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012)
Follow-up: Two-week review with liver tests, vision and a sputum specimen. Call the same day for hepatitis symptoms or any change in vision. Next scheduled visit 1896-05-01: two-week review on treatment: culture result, liver tests, vision, and release from precautions. [S]